The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Underrecognized post-CAR-T toxicities that are important to monitor in patients with DLBCL
Matthew Frank, MD, PhD, Stanford University, Stanford, CA, reviews key toxicities beyond cytokine release syndrome (CRS) and neurotoxicity that community oncologists should monitor in patients with diffuse large B-cell lymphoma (DLBCL) who received CAR-T therapy. He highlights the importance of monitoring low blood counts, secondary malignancies, and psychological effects. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
